Edition:
United Kingdom

Nevro Corp (NVRO.N)

NVRO.N on New York Stock Exchange

77.87USD
8:59pm GMT
Change (% chg)

$-1.88 (-2.36%)
Prev Close
$79.75
Open
$79.73
Day's High
$80.18
Day's Low
$77.84
Volume
56,812
Avg. Vol
94,005
52-wk High
$99.63
52-wk Low
$65.35

Chart for

About

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic... (more)

Overall

Beta: --
Market Cap(Mil.): $2,714.65
Shares Outstanding(Mil.): 29.44
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.18 16.44
EPS (TTM): -- -- --
ROI: -- 13.94 10.61
ROE: -- 16.77 14.21

BRIEF-Nevro Receives FDA Approval For Senza II

* NEVRO RECEIVES FDA APPROVAL FOR SENZA II SPINAL CORD STIMULATION SYSTEM DELIVERING HF10 THERAPY Source text for Eikon: Further company coverage:

08 Jan 2018

BRIEF-Nevro Sees Q4 Revenue $97.4 Million To $97.9 Million

* NEVRO ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FISCAL YEAR 2017 REVENUE

08 Jan 2018

BRIEF-Nevro reports third quarter 2017 financial results

* Nevro Corp - qtrly net loss per share, basic and diluted $0.21‍​ Source text for Eikon: Further company coverage:

06 Nov 2017

BRIEF-Nevro Q2 loss per share $ 0.40​

* Nevro corp - ‍nevro reiterates its expectations for worldwide revenue for 2017 to be in range of $310 to $320 million​

07 Aug 2017

Earnings vs. Estimates